Structural basis for capsid recruitment and coat formation during HSV-1 nuclear egress
- Department of Molecular Biology and Microbiology, Tufts University School of Medicine, United States
- Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles (UCLA), United States
- Molecular Biology Institute, UCLA, United States
- California NanoSystems Institute, UCLA, United States
Figures
Figure 1 with 1 supplement
Inhibition of NEC-mediated budding by UL25 constructs.
(a) The UL25 structure and a diagram of domain organization is shown along with a multiple sequence alignment of UL25 residues 45–74 from five alphaherpesviruses. Sequence alignment was generated …
-
Figure 1—source data 1
Raw data and background values collected for GUV budding assays of NEC220 in the presence of either UL25∆44 Q72A, UL25∆58 Q72A or UL25∆73.
The reported biological replicate average values (%) are the points presented in Figure 1.
- https://cdn.elifesciences.org/articles/56627/elife-56627-fig1-data1-v2.xlsx
Figure 1—figure supplement 1
NEC-UL25 binding studies.
SPR binding of UL25Δ44 Q72A (a) and UL25Δ73 (b) to NEC220-His indicating UL25 can bind the NEC if the NEC is able to form a type of scaffold. (c) ITC of NEC220 and UL25Δ44 showing these two proteins …
Figure 2 with 1 supplement
eGFP-UL25∆50 inhibits NEC budding while eGFP-UL25∆73 does not.
(a) Quantification of NEC budding in the presence of either eGFP-UL25∆50 or eGFP-UL25∆73. Each construct (except in the absence of NEC220) was tested in at least two biological replicates, each …
-
Figure 2—source data 1
Raw data and background values collected for GUV budding assays of NEC220 in the presence of either UL25∆50 Q72A, eGFP-UL25∆50 Q72A or eGFP-UL25∆73.
The reported biological replicate average values (%) are the points presented in Figure 2.
- https://cdn.elifesciences.org/articles/56627/elife-56627-fig2-data1-v2.xlsx
Figure 2—figure supplement 1
Confocal image of GUVs (red) and eGFP-UL25∆50 Q72A (green) showing that eGFP-UL25∆50 Q72A does not bind GUV membranes.
Both the ATTO-594 and eGFP channels are shown. The scale bar represents 5 μm.
Figure 3
UL25 inhibits NEC220-CBM budding to a lesser extent.
(a) NEC220-CBM budding is not inhibited to the same extent as NEC220 budding by either UL25Δ44 Q72A or eGFP-UL25Δ50 Q72A. Budding was tested at 1:1, 1:6 and 1:10 NEC220-CBM:UL25 molar ratios for …
-
Figure 3—source data 1
Raw data and background values collected for GUV budding assays of NEC220-CBM in the presence of either UL25∆44 Q72A or GFP-UL25∆50 Q72A.
The reported biological replicate average values (%) are the points presented in Figure 3.
- https://cdn.elifesciences.org/articles/56627/elife-56627-fig3-data1-v2.xlsx
Figure 4 with 2 supplements
CryoEM shows UL25∆44 Q72A inhibits NEC220 budding while UL25∆73 does not.
(a) UL25∆44 Q72A bound to the NEC220 on the outside of the unbudded lipid vesicles, forming a fence-like array (~17 nm). In the presence of UL25∆73, three scenarios have been observed: (b) NEC220 …
Figure 4—figure supplement 1
Incomplete distribution of NEC-UL25 around vesicles.
Slices of selected tomograms of NEC220/UL25∆44 Q72A-bound vesicles used to generate cryoET averages in Figure 5. Regions of either protein binding or lack of protein binding are indicated by pink …
Figure 4—figure supplement 2
Slices of selected tomograms of NEC220/UL25∆73-bound vesicles.
Selected regions of UL25∆73 aggregation are indicated by brackets along with the corresponding measurements of each selection. Scale bars represent 200 nm.
Figure 5 with 1 supplement
CryoET of UL25-mediated inhibition of NEC budding.
(a) CryoET averages of NEC220 in the presence of UL25Δ44 Q72A (top and side views). Corresponding 3D models are shown with NEC220 (pink) and UL25Δ44 Q72A (green). The vesicle bilayer is shown in …
Figure 5—figure supplement 1
CryoET averages of NEC220 in the presence of UL25Δ44 Q72A (top and side views) prior to applying five-fold symmetry.
Corresponding 3D models are shown with NEC220 (pink) and UL25Δ44 Q72A (green). The vesicle bilayer is shown in beige. The models show the UL25 layer coating the NEC layer in five-pointed stars on …
Figure 6
Models of UL25/UL25 and UL25/NEC interactions in vitro and in vivo.
(a) A schematic representation of the pentagonal HSV-1 CATC [two copies of UL25 (green and purple), two copies of C-terminal UL36 (peach and blue) and one copy of UL17 (lime green)] arrangement at …
Figure 7
A model of NEC-mediated budding in the absence and presence of UL25, in vitro.
(a) NEC-mediated budding requires only the NEC, which vesiculates membranes by forming hexagonal coats (pink) that, potentially, contain irregular defects to achieve curvature. (b) UL25∆44 Q72A …
Figure 8
A model of NEC-mediated budding in HSV-1 infected cells.
Capsid-bound UL25 induces the formation of pentagonal insertions (purple pentamers) within the NEC coat (pink hexamers and white monomers) as it is forming, which enables the formation of an NEC …
Tables
Key resources table
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Gene (HSV-1 KOS) | UL25 | Geneart | JQ673480.1 | |
| Strain, strain background (Escherichia coli) | BL21(DE3) | Kerafast | LoBSTr | Chemically competent cells |
| Recombinant DNA reagent | eGFP-N2 (plasmid) | Clontech | eGFP-N2 | |
| Recombinant DNA reagent | pKH90 (plasmid) | PMID:24916797 | UL31 1–306 | |
| Recombinant DNA reagent | pJB02 (plasmid) | PMID:24916797 | UL34 1–220 | |
| Recombinant DNA reagent | pJB104 (plasmid) | This paper | UL25∆44 | See Materials and methods, Cloning |
| Recombinant DNA reagent | pJB118 (plasmid) | This paper | NEC-CBM | See Materials and methods, Cloning |
| Recombinant DNA reagent | pJB123 (plasmid) | This paper | UL25∆73 | See Materials and methods, Cloning |
| Recombinant DNA reagent | pED03 (plasmid) | This paper | UL25∆44 Q72A | See Materials and methods, Cloning |
| Recombinant DNA reagent | pED05 (plasmid) | This paper | eGFP-UL25∆73 | See Materials and methods, Cloning |
| Recombinant DNA reagent | pED13 (plasmid) | This paper | UL25∆50 | See Materials and methods, Cloning |
| Recombinant DNA reagent | pED14 (plasmid) | This paper | eGFP-UL25∆50 | See Materials and methods, Cloning |
| Peptide, recombinant protein | UL25∆44 | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | UL25∆44 Q72A | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | UL25∆50 Q72A | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | UL25∆58 Q72A | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | UL25∆73 | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | eGFP-UL25∆50 Q72A | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | eGFP-UL25∆73 | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | NEC220 | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Peptide, recombinant protein | NEC-CBM | This paper | Purified from E. coli BL21(DE3) LoBSTr cells | |
| Chemical compound, drug | Cascade Blue hydrazide | Thermo Fisher Scientific | Thermo Fisher Scientific: C687 | |
| Software, algorithm | ImageJ | ImageJ | RRID:SCR_003070 | |
| Software, algorithm | IMOD | IMOD | RRID:SCR_003297 | |
| Other | 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate | Avanti Polar Lipids | Avanti Polar Lipids:850857 | POPA |
| Other | 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine | Avanti Polar Lipids | Avanti Polar Lipids:850457 | POPC |
| Other | 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine | Avanti Polar Lipids | Avanti Polar Lipids:840034 | POPS |
Additional files
-
Supplementary file 1
Supplementary Tables 1 and 2.
UL25∆44 Q72A/NEC particles used for cryoET averaging. List of primers used for cloning procedures described in Materials and methods.
- https://cdn.elifesciences.org/articles/56627/elife-56627-supp1-v2.docx
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/56627/elife-56627-transrepform-v2.docx
